Kura Oncology Inc [KURA] stock prices are up 4.92% to $21.76 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The KURA shares have gain 7.30% over the last week, with a monthly amount glided 21.02%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 27, February 2024, Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results. In a post published today on Yahoo Finance, – Positive preliminary combination data from KOMET-007 trial of ziftomenib in NPM1-m and KMT2A-r AML, including effective mitigation of differentiation syndrome –.
From an analyst’s perspective:
Kura Oncology Inc [NASDAQ: KURA] stock has seen the most recent analyst activity on December 22, 2023, when Mizuho initiated its Buy rating and assigned the stock a price target of $26. Previously, BofA Securities started tracking the stock with Buy rating on August 11, 2023, and set its price target to $31. On July 27, 2023, Scotiabank initiated with a Sector Perform rating and assigned a price target of $10.50 on the stock. BTIG Research started tracking the stock assigning a Buy rating and suggested a price target of $31 on May 17, 2023. Stifel initiated its recommendation with a Buy and recommended $25 as its price target on January 31, 2023. Cantor Fitzgerald started tracking with a Overweight rating for this stock on July 12, 2022, and assigned it a price target of $30. In a note dated February 15, 2022, Jefferies initiated an Buy rating and provided a target price of $35 on this stock.
The stock price of Kura Oncology Inc [KURA] has been fluctuating between $7.41 and $22.92 over the past year. Currently, Wall Street analysts expect the stock to reach $26 within the next 12 months. Kura Oncology Inc [NASDAQ: KURA] shares were valued at $21.76 at the most recent close of the market. An investor can expect a potential return of 19.49% based on the average KURA price forecast.
Analyzing the KURA fundamentals
Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 20.95 points at the first support level, and at 20.14 for the second support level. However, for the 1st resistance point, the stock is sitting at 22.25, and for the 2nd resistance point, it is at 22.74.
Kura Oncology Inc [KURA] reported earnings per share of -$0.5 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.55/share, meaning a difference of $0.05 and a surprise factor of 9.10%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.53 per share as compared to estimates of -$0.55 per share, a difference of $0.02 representing a surprise of 3.60%.
Ratios To Look Out For
It’s worth pointing out that Kura Oncology Inc [NASDAQ:KURA]’s Current Ratio is 16.71. As well, the Quick Ratio is 16.71, while the Cash Ratio is 0.05.
Transactions by insiders
Recent insider trading involved DALE STEPHEN, Chief Medical Officer, that happened on Jan 30 when 4825.0 shares were sold. Chief Medical Officer, DALE STEPHEN completed a deal on Jan 29 to sell 7158.0 shares. Meanwhile, SVP, Finance & Accounting DOYLE THOMAS JAMES sold 2318.0 shares on Jan 29.
